Summary of the call:
1. All activities ceased(my perception-cashburn for this Q is limited to 6 weeks).
2. We'll continue as a company.
3. R&D
a. Company will file for R&D grant with the tax return ? late this year.
b. Small grant from some industry program expected(or received-unsure)
- Forums
- ASX - By Stock
- DLM
- Ann: Conference Call Details - Phase 2 Clinical Trial Results
Ann: Conference Call Details - Phase 2 Clinical Trial Results, page-7
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DLM (ASX) to my watchlist
|
|||||
Last
3.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $7.227M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
DLM (ASX) Chart |
Day chart unavailable
The Watchlist
SBW
SHEKEL BRAINWEIGH LTD
Dani Nadri, Country Manager Australia
Dani Nadri
Country Manager Australia
SPONSORED BY The Market Online